Net Sales are expected to decrease by 5.9 percent Q-o-Q (down 2.4 percent Y-o-Y) to Rs 7449.4 crore, according to ICICI Securities. Sun Pharma to report net profit at 1458.4 crore down 0.9% quarter-on-quarter.

Ranbaxy deal to kick in, Halol overhang on Sun Pharma:Brokerages

Most analysts noted that the Q3 results were below their estimates, but maintained their buy rating on the stock revising the target price slightly on lower side on hopes of Halol resolution, US specialty play kicking in and normalisation of India business.

Sun Pharma Q3 profit seen up 27%; US & India biz may grow 10%

According to average of estimates of analysts polled by CNBC-TV18, revenue during the quarter may increase 11.6 percent year-on-year to Rs 7,905.3 crore, driven by Sun's authorised generic (AG) launches of Daichi Sankyo drugs in US.

Lupin pins hopes on new launches in US to fend off rivals

The company said it plans to mitigate the any loss in revenue from Glumetza and Fortamet with over 25 potential launches in the next 12 months - including some big ones such as as birth-control pill Minastrin 24, HIV drug Epzicom, hepatitis-B medication viread, among others.

Good Q3 but Dr Reddy's still far from sustainable growth: Expert

Surajit Pal, Research Analyst at Prabhudas Lilladher, said the pharma sector is undergoing a transition and all the large midcaps will underperform.

Sun Pharma Q3 PAT may dip 26.7% to Rs 1638 cr: ICICI Securities

Net Sales are expected to decrease by 2.4 percent Q-o-Q (up 9.8 percent Y-o-Y) to Rs 7773.7 crore, according to ICICI Securities.

Sun Pharma Q3 PAT may dip 26.2% to Rs 1649.5 cr: KR Choksey

Net Sales are expected to decrease by 3 percent Q-o-Q (up 6.9 percent Y-o-Y) to Rs 7529.4 crore, according to KR Choksey.

Sun Pharma Q2 show healthy but margins unsustainable: Nangra

Healthcare major Sun Pharmaceutical Industries' Profit more than doubled to Rs 2,235.1 crore in the quarter ended September 2016 compared with Rs 1,028.8 crore in year-ago period, driven by overall healthy business performance.

Sun Pharma Q2 profit seen up 52%, US sales may drive revenue

Healthcare major Sun Pharmaceutical Industries' second quarter profit is seen rising 52.3 percent year-on-year to Rs 1,685 crore on strong operational performance.

Sun Pharma Q2 PAT seen down 54.7% to Rs 1139 cr: Centrum

Net Sales are expected to decrease by 10.1 percent Q-o-Q (up 8.3 percent Y-o-Y) to Rs 7407 crore, according to Centrum.

Pharma cos may report subdued performance in Q2 FY17: Report

Domestic pharmaceutical companies are likely to report subdued sales, EBITDA and PAT figures in the second quarter of this fiscal, even as the formulations business may see a strong recovery, Reliance Securities said in its report.

Distressed sectors earnings may improve in Q2

Most analysts think business in India has most likely improved in the last three month but there may be challenges this quarter when it comes to recovery in sectors like capital goods, construction and engineering.

Sun Pharma's topline may suffer; like Aurobindo, Glenmark:Expert

Surajit Pal of Prabhudas Lilladher talks about Sun Pharma and Glenmark's June quarter earnings.

Sun Pharma Q1 net seen at Rs 1894 cr, US sales likely at $598 mn

According to a CNBC-TV18 poll, the drug major is likely to see revenue growth of 20.2 percent at Rs 7876.6 crore in Q1 against Rs 6552.2 crore in year-ago period.

Don't rush to buy these post-Q1 largecaps: Elara Cap

A number of large companies have posted results since the earnings season started Thursday last week.

Sun Pharma Q1 PAT seen up 7.6% at Rs 1844.4 cr: Religare

Sales are expected to increase by 5.2 percent Q-o-Q (up 18.8 percent Y-o-Y) to Rs 8029.8 crore, according to Religare Research.

Sun Pharma Q1 PAT seen up 16% to Rs 1988.3 cr: Edelweiss

Net Sales are expected to increase by 9.3 percent Q-o-Q (up 19.9 percent Y-o-Y) to Rs 8106.7 crore, according to Edelweiss

Q1 earnings: Which sectors will do well, which won't?

In an interview with CNBC-TV18, Pankaj Pandey of ICICI Direct talked about the brokerage's expectations from the first quarter earnings season and outlined his view on various sectors.

A tale of 2 pharma companies: Aurobindo shines, Sun Coughs

Traders cheered Aurobindo's in-line performance by sending the stock nearly 4 percent higher. But they punished Sun Pharma for missing Street estimates across the board by sending the stock down over 6 percent. CNBC-TV18's Ekta Batra and Archana Shukla crunch the numbers.

Bull vs Bear: What's the outlook on Sun Pharma?

Sun Pharma is the biggest loser on the Nifty as it missed estimates. Also, the management gave a very conservative guidance of 8-10 percent growth in consolidated sales for FY17. A bullish SP Tulsian of sptulsian.com gave a support price of Rs 700.

Sun Pharma Q4 profit seen up 113%, Gleevec may drive US sales

Sun Pharma launched Gleevec generic on February 1, 2016 with 180-day exclusivity and it has already captured around 40-50 percent market share.

Sun Pharma Q3 profit seen up 4.4%, Gleevec & Halol key

Operating profit (earnings before interest, tax, depreciation and amortisation) may increase 1.8 percent quarter-on-quarter to Rs 1,968.5 crore and margin may remain flat at 28 percent in Q3.

Sun Pharma Q2 profit seen up 171%, Halol may hit revenue

Revenue may increase 6.4 percent to Rs 6,940.9 crore during the quarter compared to Rs 6,522.2 crore in preceding quarter. Analysts feel Halol plant remediation is likely to impact core sales growth and margin.

Positive on private sector banks: Nischal Maheshwari

In an interview to CNBC-TV18, Nischal Maheshwari, Co-Head, Institutional Equities & Head-Research at Edelweiss Securities shared his readings and outlook on the upcoming earning season.

Ranbaxy integration may hurt Sun Pharma's Q1 earnings

According to average of estimates of analysts polled by CNBC-TV18, net profit is seen rising 0.6 percent sequentially to Rs 894 crore and revenue may increase 1.7 percent to Rs 6,262 crore in the quarter ended June.